STADA to work with China's Bio-Thera on Simponi biosimilar

30 May 2024
research_technology_lab_big

Bio-Thera Solutions (SH: 688177) has partnered with STADA Arzneimittel (ETR: SAZ) for the commercialization of BAT2506, a biosimilar candidate to Simponi (golimumab).

Under the agreement, Bio-Thera will handle development and manufacturing, while STADA will manage commercialization in the EU, UK, Switzerland, and other countries.

Bio-Thera will receive an upfront payment of $10 million, with potential milestone payments up to $147.5 million.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biosimilars